Eli Lilly and Company Aktie News

The majority of leading global indices reached new highs in 2024, fueled by loose financial conditions and burgeoning enthusiasm for artificial intelligence (AI). In the U.S., this rally pushed the S&P 500 to fresh highs.

Demand is high for Eli Lilly's Zepbound, and the weight-loss drug market could reach $100 billion by the end of the decade. But one thing is getting in between some potential patients and this promising drug.

NEWARK, N.J.--(BUSINESS WIRE)---- $LLY #T1D--A historic fair drug-pricing lawsuit has reached a milestone moment, according to attorneys at Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello who represent a class of those living with diabetes fighting the rising price of insulin. The law firms first began the crusade against insulin-maker Eli Lilly in 2017 and have been leading the ...

There's plenty out there that could potentially drive a broad market pullback, but there are also plenty of individual stocks due for a pullback. Irrespective how the market performs from here, these types of stocks may be in for considerable declines in price.

Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines.

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.

The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.